Anixa Biosciences, Inc. (ANIX)
Business numbers score is on the low side; smart-money score is on the high side; score for how it compares with the broader market is near the bottom of its range.
ANIX scores higher than 51% of the 1,101 tickers we compare it with (Health Care).
As of 10 October 2026, Anixa Biosciences, Inc. (ANIX) scores 41 out of 100 on the Market Census six-factor composite, which puts it at the Average score level. The score is made from six named factors: price trend, strength vs the market, company finances, insider trades, market mood and recent momentum. It records what they read on 10 October 2026, and it is not investment advice.
Updated · scores usually change about once a day
Key statistics
Market fields as reported. An em-dash means we hold no value for this ticker — most of the universe has no daily price or volume read.
- Relative volume
- 0.61× 30-day average
- 52-week range
- 2.32 – 5.46
- Market cap
- $96.30M
- Earnings date
- —
- Volume
- 217,882
- Avg. volume (30d)
- 356,166
- Open
- 2.93
- Previous close
- 2.91
- Day's range (regular session)
- 2.86 – 2.96
The last trade can be an extended-hours trade, so it can sit outside the regular-session range.
Shown without a peer ranking — we hold no percentile for these yet, so there is nothing here to locate them against.
- Beta
- 0.50
- P/E (TTM)
- —
- EPS (TTM)
- -0.30
Score breakdown · six named factors
Each bar is one part of the score, from 0 to 100. Read what the score means.
Premium data held for ANIX
- 16 SEC Form 4 insider transactions in the last 90 daysPremium
Counts of rows Market Census holds for ANIX. A dash in the factor table above means that factor has no data for this ticker — it is not a locked value. Compare plans
What the score says about ANIX right now
Anixa Biosciences, Inc. (ANIX) currently scores 41/100 on the Market Census six-factor composite, at the Average score level. ANIX is -0.34% on the day and -1.69% over five sessions as of the most recent tick. Average sits in the middle. The good and the bad in ANIX's data roughly balance out right now. ANIX's strongest factor is insider trades at 86/100 — a very strong read on insider buying and selling. Insider filings currently lean toward buying on this name — a plain read of public filings, not a signal to follow. The weakest factor is company finances at 0/100 — well below average company numbers. A low company-finances reading is the canonical "value trap" warning: technical setups on broken fundamentals don't tend to compound.
Generated from the six-factor breakdown above. Changes when the underlying scores do, usually about once a day. More on what the score means.
See ANIX in the scanner
This page is free to read with no account at all. Signing up takes an email and a password: a free account runs the scanner on the top 10 scored rows of any scan, keeps one saved screen, a 5-ticker watchlist, and opens 12 ticker detail pages a day. The card is what starts a 30-day Premium trial — $0 that day, then $19.99/month from day 30, cancel online any time before then — and that is what turns on every matching row instead of the first 10, alerts, the 200-ticker watchlist and recent insider buys (SEC Form 4).
Recent ANIX news
Latest headlines that name Anixa Biosciences, one per story, sourced from Market Census’s news feed (Polygon/Massive + Finnhub).
- Anixa Biosciences Announces First Case of Stable Disease for Three Months in Ovarian Cancer CAR-T Clinical TrialYahoo
- Anixa Biosciences Participant In Its Current Phase 1 Study Of FSHR-Targeted CAR-T Therapy For Recurrant Ovarian Cancer Demonstrates Stable Disease After 90 Days Of Treatment; Patient Was Treated In Fifth Dose CohortBenzinga
- Anixa Biosciences Announces Treatment of Second Patient in the Fifth Cohort of its Ovarian Cancer CAR-T Clinical TrialYahoo
- Anixa Biosciences Announces Second Patient Has Been Treated In Fifth Cohort Of Its Ongoing Phase 1, Dose-Escalating, Clinical Trial Evaluating FSHR-Targeted CAR-T Therapy For Recurrent Ovarian CancerBenzinga
- Anixa Biosciences Granted First Australian Patent for its Breast Cancer Vaccine, Broadening Global Protection Through 2040Yahoo
We hide 1 more that told readers to buy or sell, or gave a price target.
Saved snapshot; the news and prices on this page can be an hour old or more.
Similar setups in Health Care right now
Six health care tickers whose composite scores are closest to ANIX’s 41, all within 1 point.
Sorted by closeness to ANIX’s composite score within Health Care. Saved snapshot; can be an hour old or more. Run the full scanner →
Prices delayed about 15 minutes; scores usually change about once a day. Not investment advice — see risk disclosure.